Description
Dexmedetomidine is a highly selective α2-adrenergic receptor agonist. It is mainly used clinically for the sedation of tracheal intubation and mechanical ventilation in surgical patients undergoing general anesthesia. It was developed by Abbott and Orion Corp. According to CRI’s market research, as of the end of 2020, the original drug of Dexmedetomidine has not been listed in China. In 2009, Jiangsu Hengrui Medicine Co., Ltd. first imitated the drug and was approved to be listed in China. By 2020, there are 5 manufacturers in the Chinese Dexmedetomidine market, of which Yangtze River Pharmaceutical is the main manufacture.
According to CRI’s market research, the sales value of Dexmedetomidine in the Chinese market increased year by year at a steady growth rate from 2016 to 2019. Especially, affected by the “4+7” centralized procurement by the Chinese government in 2018, its sales volume increased by 29.66% year-on-year, and sales increased by nearly 18% year-on-year. Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of Dexmedetomidine in the Chinese market decreased to CNY 984 million in 2020, a year-on-year decrease of 3.45%. The CAGR of the sales value of Dexmedetomidine in the Chinese market is 11.8% from 2016 to 2020, which is a very high level.
CRI expects that the sales of Dexmedetomidine in the Chinese market will have a restorative growth from 2016 to 2020 as the alleviation of the COVID-19 epidemic. In addition, as a new type of α2 adrenergic receptor agonist, Dexmedetomidine has significant advantages such as high selectivity, a strong sedative, and analgesic effects, anti-anxiety and hemodynamic stability. Based on these advantages, the sales value and sales volume of Dexmedetomidine still have room to rise.
Topics Covered:
-The impact of COVID-19 on China’s Dexmedetomidine market
– Sales value of China’s Dexmedetomidine 2016-2020
– Competitive landscape of China’s Dexmedetomidine market
– Prices of Dexmedetomidine in China
– Prices of Dexmedetomidine in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Dexmedetomidine market
– Prospect of China’s Dexmedetomidine market from 2021 to 2025
Table of Contents
1 Relevant Concepts of Dexmedetomidine
1.1 Indications for Dexmedetomidine
1.2 Development of Dexmedetomidine in China
1.3 Governmental Approval of Dexmedetomidine in China
1.4 The Impact of COVID-19 on Dexmedetomidine Sales in China
2 Sales of Dexmedetomidine in China, 2016-2020
2.1 Sales Value of Dexmedetomidine
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Dexmedetomidine
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Dexmedetomidine by Dosage Form in China, 2016-2020
2.3.1 Injection
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Dexmedetomidine Manufacturers in China in 2020
3.1 Analysis of Market Share of Major Dexmedetomidine Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Yangtze River Pharmaceutical Group Co.,Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Youbituo (Yangtze River Pharmaceutical Group Co.,Ltd.’s Dexmedetomidine) in China
3.3 Jiangsu Hengrui Medicine Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Aibeining (Jiangsu Hengrui Medicine Co., Ltd.’s Dexmedetomidine) in China
3.4 Jiangsu Nhwa Pharmaceutical Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Yisi (Jiangsu Nhwa Pharmaceutical Co., Ltd.’s Dexmedetomidine) in China
3.5 Sichuan Guorui Pharmaceutical Co., Ltd.
3.5.1 Enterprise Profile
3.5.2 Sales of Leweijia (Sichuan Guorui Pharmaceutical Co., Ltd.’s Dexmedetomidine) in China
3.6 Cisen Pharmaceutical Co., Ltd.
3.6.1 Enterprise Profile
3.6.2 Sales of Chenjiao (Cisen Pharmaceutical Co., Ltd.’s Dexmedetomidine) in China
4 Prices of Dexmedetomidine for Different Manufacturers in China, 2020-2021
4.1 Yangtze River Pharmaceutical Group Co.,Ltd. (Youbituo)
4.2 Jiangsu Hengrui Medicine Co., Ltd. (Aibeining)
4.3 Jiangsu Nhwa Pharmaceutical Co., Ltd. (Yisi)
4.4 Sichuan Guorui Pharmaceutical Co., Ltd. (Leweijia)
4.5 Cisen Pharmaceutical Co., Ltd. (Chenjiao)
5 Prospect of Chinese Dexmedetomidine Market, 2021-2025
5.1 Influential Factors of Chinese Dexmedetomidine Market Development
5.1.1 The Impact of COVID-19 on Chinese Dexmedetomidine Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information About Dexmedetomidine Injection Registration in China
Chart Sales Value of Dexmedetomidine Injection over the World
Chart Sales Value of Dexmedetomidine Injection in China, 2016-2020
Chart Sales Value of Dexmedetomidine Injection in China by Region, 2016-2020
Chart Sales Volume of Dexmedetomidine Injection in China, 2016-2020
Chart Sales Volume of Dexmedetomidine Injection in China by Region, 2016-2020
Chart Market Share by Sales Value of Top Dexmedetomidine Injection Manufacturers in China, 2016-2020
Chart Sales Value and Volume of Youbituo in China, 2016-2020
Chart Sales Value and Volume of Aibeining in China, 2016-2020
Chart Sales Value and Volume of Yisi in China, 2016-2020
Chart Sales Value and Volume of Leweijia in China, 2016-2020
Chart Sales Value and Volume of Chenjiao in China, 2016-2020
Chart Referential Prices of Youbituo in China by Region, 2020-2021
Chart Referential Prices of Aibeining in China by Region, 2020-2021
Chart Referential Prices of Yisi in China by Region, 2020-2021
Chart Referential Prices of Leweijia in China by Region, 2020-2021
Chart Referential Prices of Chenjiao in China by Region, 2020-2021
Chart Forecast on Sales Value of Dexmedetomidine Injection in China, 2021-2025
Chart Forecast on Sales Volume of Dexmedetomidine Injection in China, 2021-2025
